This is the first study proposed to evaluate the chemopreventive effect of aspirin and metformin combination therapy in patients with rectal ACF. Given its role as an analgesic, antipyretic and agent for cardiovascular prophylaxis, aspirin has become one of the most commonly used drugs. Many studies have provided considerable evidence demonstrating its potential for the prevention of CRC. Aspirin exerts its anticancer effects through several interconnected mechanisms, including prostaglandin synthesis and catabolism in epithelial cells [
30,
31]; inhibition of WNT β-catenin signalling [
32,
33]; inactivation of platelets [
34,
35] and the host immune response [
31,
36]. Aspirin may also act through several other unknown mechanisms. Furthermore, aspirin may has been hypothesized to act synergistically with other agents [
37]. Further study is needed to clear the chemopreventive effect of aspirin. Metformin (1,1-dimethylbiguanide hydrochloride) is a biguanide derivative that is widely used for the treatment of diabetes mellitus [
38]. Metformin activates AMPK, which inhibits the mammalian target of rapamycin (mTOR) pathway [
39]. The mTOR pathway plays an important role in the regulation of cellular protein translational machinery and cell proliferation [
40]. The best-characterized downstream effector of mTOR is S6 kinase, which regulates the initiation and elongation phases of translation [
41]. Activation of the mTOR pathway has been shown to accelerate cell cycle progression from G1 to S in CRC DLD-1 cells [
42]. Therefore, AMPK activation may inhibit cell growth and proliferation by suppressing protein synthesis, thereby having a potent antiproliferative effect. Recent evidence indicates that metformin has a suppressive effect on tumorigenesis and cancer cell growth [
43‐
45]. In one study, metformin was demonstrated to activate AMPK and consequently decrease cellular proliferative activity, to produce a general decrease in protein synthesis in vitro in human breast carcinoma cells [
43]. Metformin was also shown to inhibit the proliferation of human prostate cancer cells [
45]. In addition, we performed a RCT and we showed that metformin reduced the incidence of new polyps in patients after polypectomy of the colon [
16]. However, similar to aspirin, the chemopreventive effective was limited. In this study, we aim to evaluate the chemopreventive effect of aspirin and metformin combination therapy in patients with rectal ACF and determine whether the combined use of aspirin and metformin produces a stronger chemopreventive effect than each drug alone. Because we hypothesize that both aspirin and combination therapy may have a chemopreventive effect, a higher number of baseline ACFs (> 10) was needed to detect a difference between the two treatment effects. We previously reported a mean number of ACFs in adenomas of 6.2 ± 7.0 [
24], which is why we set > 10 ACFs as an inclusion criterion. Consequently, we expect the trial to take longer because of the small number of patients who meet the inclusion criteria.
This trial may have the following limitations. First, ACFs are considered as a reliable surrogate biomarker of CRC [
22], although their biological significance still remains controversial. However, setting study endpoint as ACF has large merit to reduce efforts because ACFs are quantitative and it is possible to observe changes in a short period of time. Thus, we devised a trial using ACF as the primary endpoint to evaluate the chemopreventive effects of aspirin and metformin combination therapy. Second, an intervention period of 8 weeks may be too short to allow the reliable detection of differences between the groups. However, we showed in a previous study that oral administration of metformin for 1 month suppressed the formation of colorectal ACF in humans. Other reports show that ACFs decrease in number in 8 weeks with the use of NSAIDs [
23]. Therefore, we think that an intervention period of 8 weeks would be sufficient to evaluate the changes in the number of ACF. We previously conducted a short-term chemoprevention trial of metformin for colorectal ACF, and we showed the suppressive effect of the drug on the formation of ACF. Thereafter, we conducted a long-term metformin chemoprevention trial for colorectal polyps. We propose to repeat the same steps for the chemoprevention trial to investigate the combined use of aspirin and metformin. Third, our study lacks dose-response data. However, low-dose aspirin (100 mg/d) is used worldwide with reported chemopreventive effects on CRC and adenoma. Furthermore, we previously reported the effect of low-dose metformin (250 mg/d) on colorectal adenoma and ACF. Finally, our study lacks a metformin alone arm and double placebo arm, while the use of aspirin alone has not been established to suppress to the formation of ACFs. However, aspirin is one of the most efficiacious chemopreventive agents for the treatment of colorectal adenoma and CRC, which is why we used aspirin alone as the control arm in the present study. A four-arm study using a double placebo is needed in the future to investigate the combination effect of metformin and aspirin.
If this combination therapy was found to be more effective for the prevention of CRC, the impact would be significant. Therefore, we consider it of interest to determine whether the combined use of aspirin and metformin shows a stronger chemopreventive effect on the formation of human colorectal ACFs than either aspirin or metformin alone.